ECS Botanics Holdings Ltd

ASX:ECS Stock Report

Market Cap: AU$21.9m

ECS Botanics Holdings Past Earnings Performance

Past criteria checks 4/6

ECS Botanics Holdings has been growing earnings at an average annual rate of 50.4%, while the Pharmaceuticals industry saw earnings growing at 35.1% annually. Revenues have been growing at an average rate of 65.1% per year. ECS Botanics Holdings's return on equity is 6.8%, and it has net margins of 9.6%.

Key information

50.4%

Earnings growth rate

54.1%

EPS growth rate

Pharmaceuticals Industry Growth31.2%
Revenue growth rate65.1%
Return on equity6.8%
Net Margin9.6%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Lacklustre Performance Is Driving ECS Botanics Holdings Ltd's (ASX:ECS) 26% Price Drop

Nov 11
Lacklustre Performance Is Driving ECS Botanics Holdings Ltd's (ASX:ECS) 26% Price Drop

There's No Escaping ECS Botanics Holdings Ltd's (ASX:ECS) Muted Earnings Despite A 38% Share Price Rise

Sep 27
There's No Escaping ECS Botanics Holdings Ltd's (ASX:ECS) Muted Earnings Despite A 38% Share Price Rise

ECS Botanics Holdings Ltd's (ASX:ECS) Shares Lagging The Market But So Is The Business

Aug 12
ECS Botanics Holdings Ltd's (ASX:ECS) Shares Lagging The Market But So Is The Business

There Is A Reason ECS Botanics Holdings Ltd's (ASX:ECS) Price Is Undemanding

Apr 03
There Is A Reason ECS Botanics Holdings Ltd's (ASX:ECS) Price Is Undemanding

ECS Botanics Holdings Ltd's (ASX:ECS) Share Price Could Signal Some Risk

Sep 06
ECS Botanics Holdings Ltd's (ASX:ECS) Share Price Could Signal Some Risk

ECS Botanics Holdings (ASX:ECS) Is In A Good Position To Deliver On Growth Plans

Feb 24
ECS Botanics Holdings (ASX:ECS) Is In A Good Position To Deliver On Growth Plans

Revenue & Expenses Breakdown

How ECS Botanics Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:ECS Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2420260
31 Mar 2420260
31 Dec 2320260
30 Sep 2318160
30 Jun 2315050
31 Dec 2210220
30 Sep 227120
30 Jun 225020
31 Mar 225-340
31 Dec 213-440
30 Sep 212-440
30 Jun 211-440
31 Mar 211-440
31 Dec 201-440
30 Sep 201-430
30 Jun 201-520
31 Dec 190-410
30 Sep 190-210
30 Jun 190-100

Quality Earnings: ECS has a high level of non-cash earnings.

Growing Profit Margin: ECS's current net profit margins (9.6%) are higher than last year (3.2%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ECS has become profitable over the past 5 years, growing earnings by 50.4% per year.

Accelerating Growth: ECS's earnings growth over the past year (289.8%) exceeds its 5-year average (50.4% per year).

Earnings vs Industry: ECS earnings growth over the past year (289.8%) exceeded the Pharmaceuticals industry 26.6%.


Return on Equity

High ROE: ECS's Return on Equity (6.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 00:40
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ECS Botanics Holdings Ltd is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Stuart RobertsPitt Street Research Pty Ltd.